Nanotechnology-based photodynamic therapy for neovascular disease using a supramolecular nanocarrier loaded with a dendritic photosensitizer

被引：159

作者：

Ideta, R

Tasaka, F

Jang, WD

Nishiyama, N

Zhang, GD

Harada, A

Yanagi, Y

Tamaki, Y

Aida, T

Kataoka, K

机构：

[1] Univ Tokyo, Grad Sch Engn, Dept Mat Sci & Engn, Bunkyo Ku, Tokyo 1138656, Japan

[2] Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Bunkyo Ku, Tokyo 1138655, Japan

[3] Univ Tokyo, Grad Sch Med, Ctr Dis Biol & Investigat Med, Bunkyo Ku, Tokyo 1130033, Japan

[4] Osaka Prefecture Univ, Dept Appl Mat Sci, Sakai, Osaka 5998531, Japan

[5] Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan

[6] Santen Pharmaceut Co Ltd, Div Res & Dev, Ikoma, Nara 6300101, Japan

来源：

NANO LETTERS | 2005年 / 5卷 / 12期

关键词：

D O I：

10.1021/nl051679d

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Photodynamic therapy (PDT) for exudative age-related macular degeneration (AMD) was evaluated using a supramolecular nanomedical device, that is, a novel dendritic photosensitizer (DP) encapsulated by a polymeric micelle formulation. The characteristic dendritic structure of the DP prevents aggregation of its core sensitizer, thereby inducing a highly effective photochemical reaction. With its highly selective accumulation on choroidal neovascularization (CNV) lesions, this treatment resulted in a remarkably efficacious CNV occlusion with minimal unfavorable phototoxicity.

引用

页码：2426 / 2431

页数：6

共 23 条

[21]

Wormald R, 2003, Cochrane Database of Systematic Reviews, DOI [10.1002/14651858.CD002030, DOI 10.1002/14651858.CD002030]

[22] Subconjunctival doxifluridine administration suppresses rat choroidal neovascularization through activated thymidine phosphorylase [J].